ADMA Biologics, Inc. (ADMA) P/E Ratio History
UndervaluedTrading at 16.2x vs 5Y avg 32.4x · 22th percentile · Below historical baseline · Data 2024–2026
Loading P/E history...
P/E Ratio Analysis
As of September 24, 2026, ADMA Biologics, Inc. (ADMA) trades at a price-to-earnings ratio of 16.2x, with a stock price of $9.70 and trailing twelve-month earnings per share of $0.73.
The current P/E is 50% below its 5-year average of 32.4x. Over the past five years, ADMA's P/E has ranged from a low of 12.0x to a high of 80.9x, placing the current valuation at the 22th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, ADMA trades at a 32% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.
Relative to the broader market, ADMA trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ADMA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ADMA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ADMA P/E vs Peers
Commercial Specialty Pharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $6B | 11.1Lowest | - | +148%Best | |
| $10B | 13.6 | - | +143% | |
| $13B | 43.9 | 1.91 | -25% | |
| $13B | 18.9 | 0.78Best | -39% | |
| $60B | 46.6 | - | +90% | |
| $1B | 31.2 | - | -46% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ADMA Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $8.37 | $0.70 | 12.0x | -63% |
| FY2026 Q1 | - | $9.01 | $0.68 | 13.3x | -59% |
| FY2025 Q4 | Dec 31 2025 | $18.24 | $0.60 | 30.4x | -6% |
| FY2025 Q3 | - | $14.66 | $0.86 | 17.0x | -47% |
| FY2025 Q2 | Jun 30 2025 | $18.21 | $0.86 | 21.2x | -35% |
| FY2025 Q1 | Mar 31 2025 | $19.84 | $0.85 | 23.3x | -28% |
| FY2024 Q4 | - | $17.15 | $0.82 | 21.0x | -35% |
| FY2024 Q3 | Sep 30 2024 | $19.99 | $0.28 | 72.1x | +123% |
| FY2024 Q2 | Jun 30 2024 | $11.18 | $0.14 | 80.9x | +150% |
Average P/E for displayed period: 32.4x
ADMA Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ADMA — Frequently Asked Questions
Quick answers to the most common questions about buying ADMA stock.
What is ADMA's P/E ratio?
ADMA Biologics, Inc. (ADMA) trailing twelve-month P/E ratio is 16.2x, based on TTM diluted EPS of $0.73. The 5-year average P/E is 32.4x and the historical range spans 12.0x to 80.9x.
Is ADMA stock overvalued or undervalued?
ADMA trades at 16.2x P/E, below its 5-year average of 32.4x. At the 22th percentile of its historical range (12.0x–80.9x), the stock is priced at a discount to its own history.
Is ADMA stock expensive?
No, ADMA is not expensive on a historical basis. The current P/E of 16.2x is below the 5-year average of 32.4x and sits at the 22th percentile of its valuation range.
What is ADMA's historical P/E range?
Over the past 5 years, ADMA's P/E ratio has ranged from 12.0x to 80.9x, with a median of 21.2x and an average of 32.4x. The current P/E of 16.2x places the stock at the 22th percentile of this range. Full historical data spans 2024–2026.
How does ADMA's P/E compare to the S&P 500?
ADMA trades at 16.2x P/E versus the S&P 500 median of 25.3x. The 36% discount to the market suggests lower growth expectations or perceived higher risk.
How does ADMA's valuation compare to Healthcare peers?
ADMA Biologics, Inc. P/E of 16.2x compares to the Healthcare sector median of 23.7x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ADMA's PEG ratio?
ADMA PEG ratio is N/A, based on a P/E of 16.2x and EPS growth of -25.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ADMA's earnings yield?
ADMA earnings yield is 6.19%, the inverse of its 16.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.